Acadia Pharmaceuticals (ACAD) Bullish Stance Reiterated at Cowen; All Eyes on PDP PDUFA, ADP Enrollment
Tweet Send to a Friend
Cowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
